Global /France /Healthcare /Biotechnology /PHXM

PHAXIAM Therapeutics S.A.

PHXM

• EPA: PHXM • Delayed

0.1005EUR 0%

0.1167 USD

As of 5 June 2026, PHAXIAM Therapeutics S.A. has a market cap of $1.17M USD, ranking #48237 globally and #602 in France. It ranks #4285 in the Healthcare sector, and #834 in the Biotechnology industry.

Global Rank

48237

Country Rank

602

Sector Rank

4285

Industry Rank

834

Key Stats

Market Cap

$1.17MUSD

1.01M EUR

Revenue (TTM)

$2.48MUSD

2.14M EUR

EBITDA (TTM)

-$21.95MUSD

-18.9M EUR

Net Income (TTM)

-$25.43MUSD

-21.92M EUR

Company Profile

Country (HQ)

France

Sector

Healthcare

Industry

Biotechnology

CEO

Thibaut Fayet open_in_new

Employees

Founded

2004

Website

phaxiam.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-	-15%	-85%	-94%	-94%	-95%	-99%	-100%

News

Markets

Exchange	Ticker	Price	Quotes
Euronext Paris (EPA) MIC: XPAR PRIMARY	PHXM PHAXIAM Therapeutics SA ISIN: FR001400K4B1 Shares Out.: Shares Outstanding: 10.05M¹ Shares Float: 9.877M² TV: TradingView: EURONEXT: PHXM SA: Stock Analysis: EPA: PHXM YF: Yahoo Finance: PHXM.PA GF: Google Finance: EPA: PHXM BA: Barron's: PHXM MS: Morningstar: XPAR: PHXM	0.1005 EUR	TV: TradingView: EURONEXT: PHXM SA: Stock Analysis: EPA: PHXM YF: Yahoo Finance: PHXM.PA GF: Google Finance: EPA: PHXM BA: Barron's: PHXM MS: Morningstar: XPAR: PHXM
London Stock Exchange (LSE / LON) MIC: XLON	0QSS PHAXIAM Therapeutics SA ISIN: FR001400K4B1 TV: TradingView: LSE: 0QSS SA: Stock Analysis: LON: 0QSS YF: Yahoo Finance: 0QSS.L GF: Google Finance: LON: 0QSS BA: Barron's: 0QSS MS: Morningstar: XLON: 0QSS	0.1005 EUR	TV: TradingView: LSE: 0QSS SA: Stock Analysis: LON: 0QSS YF: Yahoo Finance: 0QSS.L GF: Google Finance: LON: 0QSS BA: Barron's: 0QSS MS: Morningstar: XLON: 0QSS

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.coli), Pseudomonas aeruginosa (P.aeruginosa), and Staphylococcus aureus (S.aureus). The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. The company was incorporated in 2004 and is headquartered in Lyon, France.

Similar Companies

Industry: Biotechnology (France)

Name	Market Cap (USD) diff.	PE	Country
Virbac S.A. EPA: VIRP	$3.56B 3.07B EUR 303K%	20.3	France
Inventiva S.A. EPA: IVA	$1.01B 873.41M EUR 86K%	-	France
Valneva SE EPA: VLA	$486.48M 419.44M EUR 41K%	-	France
Genfit S.A. EPA: GNFT	$467.24M 402.84M EUR 40K%	-	France
Transgene S.A. EPA: TNG	$238.24M 205.41M EUR 20K%	-	France
Euroapi S.A. EPA: EAPI	$150.15M 129.46M EUR 13K%	-	France

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 16M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 14M%	19.0	United States
argenx SE EBR: ARGX	$48.01B 41.39B EUR 4M%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.36B 68.19T KRW 4M%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.98B 60.27B AUD 4M%	29.3	Australia
Lonza Group AG SIX: LONN	$42.55B 33.71B CHF 4M%	37.2	Switzerland

chevron_leftBack